Safety of WT1 and PR1 peptide vaccination for patients with myelodysplastic syndrome (MDS)

Trial Profile

Safety of WT1 and PR1 peptide vaccination for patients with myelodysplastic syndrome (MDS)

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs PR1 peptide vaccine (Primary) ; WT1 peptide vaccine (Primary) ; Montanide ISA-51; Sargramostim
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2007 Status changed from recruiting to completed.
    • 06 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top